Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Insider activity.

<< Previous

Bullboard Posts

Next >>

Post by jh1970on Dec 12, 2024 4:40pm

246 Views

Post# 36359852

Insider activity.

iled 2024-12-12 10:10 Tx date 2024-12-09	$ONC Oncolytics Biotech Inc.	Coffey, Matthew 4 - Director of Issuer 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+15,061 vol	122,654
Filed 2024-12-12 10:10 Tx date 2024-12-09	$ONC Oncolytics Biotech Inc.	Coffey, Matthew 4 - Director of Issuer 5 - Senior Officer of Issuer Direct Ownership	Rights Restricted Share Units 57 - Exercise of rights	-31,267 vol	116,333
Filed 2024-12-12 10:09 Tx date 2024-12-11	$ONC Oncolytics Biotech Inc.	Coffey, Matthew 4 - Director of Issuer 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	-300,000 vol	1,355,368
Filed 2024-12-12 10:06 Tx date 2024-12-09	$ONC Oncolytics Biotech Inc.	Levin, Amy 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+3,164 vol	4,393
Filed 2024-12-12 10:06 Tx date 2024-12-09	$ONC Oncolytics Biotech Inc.	Levin, Amy 5 - Senior Officer of Issuer Direct Ownership	Rights Restricted Share Units 57 - Exercise of rights	-5,067 vol	14,067
Filed 2024-12-12 10:04 Tx date 2024-12-11	$ONC Oncolytics Biotech Inc.	Levin, Amy 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	-30,000 vol	178,400
Filed 2024-12-12 10:02 Tx date 2024-12-09	$ONC Oncolytics Biotech Inc.	Look, Kirk 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+20,700 vol	75,128
Filed 2024-12-12 10:01 Tx date 2024-12-09	$ONC Oncolytics Biotech Inc.	Look, Kirk 5 - Senior Officer of Issuer Direct Ownership	Rights Restricted Share Units 57 - Exercise of rights	-20,700 vol	60,200
Filed 2024-12-12 10:00 Tx date 2024-12-11	$ONC Oncolytics Biotech Inc.	Look, Kirk 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	-250,000 vol	707,120
Filed 2024-12-12 09:57 Tx date 2024-12-09	$ONC Oncolytics Biotech Inc.	Heineman, Thomas 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+20,700 vol	39,666